These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 14978136)

  • 1. Rituximab infusion promotes rapid complement depletion and acute CD20 loss in chronic lymphocytic leukemia.
    Kennedy AD; Beum PV; Solga MD; DiLillo DJ; Lindorfer MA; Hess CE; Densmore JJ; Williams ME; Taylor RP
    J Immunol; 2004 Mar; 172(5):3280-8. PubMed ID: 14978136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Binding of submaximal C1q promotes complement-dependent cytotoxicity (CDC) of B cells opsonized with anti-CD20 mAbs ofatumumab (OFA) or rituximab (RTX): considerably higher levels of CDC are induced by OFA than by RTX.
    Pawluczkowycz AW; Beurskens FJ; Beum PV; Lindorfer MA; van de Winkel JG; Parren PW; Taylor RP
    J Immunol; 2009 Jul; 183(1):749-58. PubMed ID: 19535640
    [TBL] [Abstract][Full Text] [Related]  

  • 3. An anti-C3b(i) mAb enhances complement activation, C3b(i) deposition, and killing of CD20+ cells by rituximab.
    Kennedy AD; Solga MD; Schuman TA; Chi AW; Lindorfer MA; Sutherland WM; Foley PL; Taylor RP
    Blood; 2003 Feb; 101(3):1071-9. PubMed ID: 12393727
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exhaustion of cytotoxic effector systems may limit monoclonal antibody-based immunotherapy in cancer patients.
    Beurskens FJ; Lindorfer MA; Farooqui M; Beum PV; Engelberts P; Mackus WJ; Parren PW; Wiestner A; Taylor RP
    J Immunol; 2012 Apr; 188(7):3532-41. PubMed ID: 22368276
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrice-weekly low-dose rituximab decreases CD20 loss via shaving and promotes enhanced targeting in chronic lymphocytic leukemia.
    Williams ME; Densmore JJ; Pawluczkowycz AW; Beum PV; Kennedy AD; Lindorfer MA; Hamil SH; Eggleton JC; Taylor RP
    J Immunol; 2006 Nov; 177(10):7435-43. PubMed ID: 17082663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Within peripheral blood mononuclear cells, antibody-dependent cellular cytotoxicity of rituximab-opsonized Daudi cells is promoted by NK cells and inhibited by monocytes due to shaving.
    Beum PV; Lindorfer MA; Taylor RP
    J Immunol; 2008 Aug; 181(4):2916-24. PubMed ID: 18684983
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibodies That Efficiently Form Hexamers upon Antigen Binding Can Induce Complement-Dependent Cytotoxicity under Complement-Limiting Conditions.
    Cook EM; Lindorfer MA; van der Horst H; Oostindie S; Beurskens FJ; Schuurman J; Zent CS; Burack R; Parren PW; Taylor RP
    J Immunol; 2016 Sep; 197(5):1762-75. PubMed ID: 27474078
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Real-time analysis of the detailed sequence of cellular events in mAb-mediated complement-dependent cytotoxicity of B-cell lines and of chronic lymphocytic leukemia B-cells.
    Lindorfer MA; Cook EM; Tupitza JC; Zent CS; Burack R; de Jong RN; Beurskens FJ; Schuurman J; Parren PW; Taylor RP
    Mol Immunol; 2016 Feb; 70():13-23. PubMed ID: 26690706
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mechanism of action of type II, glycoengineered, anti-CD20 monoclonal antibody GA101 in B-chronic lymphocytic leukemia whole blood assays in comparison with rituximab and alemtuzumab.
    Bologna L; Gotti E; Manganini M; Rambaldi A; Intermesoli T; Introna M; Golay J
    J Immunol; 2011 Mar; 186(6):3762-9. PubMed ID: 21296976
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The shaving reaction: rituximab/CD20 complexes are removed from mantle cell lymphoma and chronic lymphocytic leukemia cells by THP-1 monocytes.
    Beum PV; Kennedy AD; Williams ME; Lindorfer MA; Taylor RP
    J Immunol; 2006 Feb; 176(4):2600-9. PubMed ID: 16456022
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring of the Complement System Status in Patients With B-Cell Malignancies Treated With Rituximab.
    Felberg A; Taszner M; Urban A; Majeranowski A; Jaskuła K; Jurkiewicz A; Stasiłojć G; Blom AM; Zaucha JM; Okrój M
    Front Immunol; 2020; 11():584509. PubMed ID: 33329558
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59.
    Golay J; Lazzari M; Facchinetti V; Bernasconi S; Borleri G; Barbui T; Rambaldi A; Introna M
    Blood; 2001 Dec; 98(12):3383-9. PubMed ID: 11719378
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutations resulting in the formation of hyperactive complement convertases support cytocidal effect of anti-CD20 immunotherapeutics.
    Felberg A; Urban A; Borowska A; Stasiłojć G; Taszner M; Hellmann A; Blom AM; Okrój M
    Cancer Immunol Immunother; 2019 Apr; 68(4):587-598. PubMed ID: 30725204
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Complement activation and C3b deposition on rituximab-opsonized cells substantially blocks binding of phycoerythrin-labeled anti-mouse IgG probes to rituximab.
    Beum PV; Kennedy AD; Li Y; Pawluczkowycz AW; Williams ME; Taylor RP
    J Immunol Methods; 2004 Nov; 294(1-2):37-42. PubMed ID: 15604014
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocaratuzumab, an Fc-engineered antibody demonstrates enhanced antibody-dependent cell-mediated cytotoxicity in chronic lymphocytic leukemia.
    Cheney CM; Stephens DM; Mo X; Rafiq S; Butchar J; Flynn JM; Jones JA; Maddocks K; O'Reilly A; Ramachandran A; Tridandapani S; Muthusamy N; Byrd JC
    MAbs; 2014; 6(3):749-55. PubMed ID: 24594909
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
    Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
    Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of the in vitro effects of the anti-CD20 antibodies rituximab and GA101 on chronic lymphocytic leukaemia cells.
    Patz M; Isaeva P; Forcob N; Müller B; Frenzel LP; Wendtner CM; Klein C; Umana P; Hallek M; Krause G
    Br J Haematol; 2011 Feb; 152(3):295-306. PubMed ID: 21155758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of two anti-CD5 monoclonal antibodies synergistically induces complement-dependent cytotoxicity of chronic lymphocytic leukaemia cells.
    Klitgaard JL; Koefoed K; Geisler C; Gadeberg OV; Frank DA; Petersen J; Jurlander J; Pedersen MW
    Br J Haematol; 2013 Oct; 163(2):182-93. PubMed ID: 23927424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human lymphocytic B-leukemia cell line treatment with the bacterial toxin listeriolysin O and rituximab (anti-CD20 antibody): Effects of similar localization of their receptors.
    Gryzik M; Grzywocz Z; Wasilewska D; Kawiak J; Stachowiak R; Bielecki J; Hoser G
    Int J Immunopathol Pharmacol; 2015 Sep; 28(3):329-40. PubMed ID: 26216910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complement activation on B lymphocytes opsonized with rituximab or ofatumumab produces substantial changes in membrane structure preceding cell lysis.
    Beum PV; Lindorfer MA; Beurskens F; Stukenberg PT; Lokhorst HM; Pawluczkowycz AW; Parren PW; van de Winkel JG; Taylor RP
    J Immunol; 2008 Jul; 181(1):822-32. PubMed ID: 18566448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.